Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001531398 | SCV001746476 | uncertain significance | not provided | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV002246241 | SCV002516990 | uncertain significance | not specified | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002570541 | SCV003531971 | uncertain significance | Inborn genetic diseases | 2022-08-11 | criteria provided, single submitter | clinical testing | The c.1175G>A (p.R392Q) alteration is located in exon 14 (coding exon 14) of the DOCK3 gene. This alteration results from a G to A substitution at nucleotide position 1175, causing the arginine (R) at amino acid position 392 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
OMIM | RCV001253774 | SCV001429647 | pathogenic | Neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia | 2020-08-13 | no assertion criteria provided | literature only |